Microphthalmos associated with dartmouth combination chemotherapy in pregnancy : A case report

• Published in: Journal of reproductive medicine Vol. 52; no. 6; pp. 575 - 576
• Main Authors: LI, Raymond Hang Wun, WING HUNG TAM, PAK CHEUNG NG, MOK, Tony Shu Kam, TAM, Barbara, TZE KIN LAU
• Format: Journal Article
• Language: English
• Published: Saint-Louis, MO Science 01-06-2007
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Biological and medical sciences; Carmustine - adverse effects; Cisplatin - adverse effects; Dacarbazine - adverse effects; Dermatology; Female; Gynecology. Andrology. Obstetrics; Humans; Infant, Newborn; Liver Neoplasms - drug therapy; Liver Neoplasms - secondary; Male; Medical sciences; Melanoma - drug therapy; Melanoma - secondary; Microphthalmos - chemically induced; Pregnancy; Pregnancy Complications, Neoplastic - drug therapy; Pregnancy Trimester, First - drug effects; Pregnancy Trimester, Second - drug effects; Skin Neoplasms - drug therapy; Skin Neoplasms - pathology; Tamoxifen - adverse effects; Tumors of the skin and soft tissue. Premalignant lesions; Andrology; Drug combination; Gynecology; combination chemotherapy; melanoma; Malignant tumor; Metastasis; Obstetrics; Case study; Pregnancy; Malignant melanoma; microphthalmos; Complication; Female; Combined treatment; pregnancy complications
• ISSN: 0024-7758; 1943-3565

Use of Dartmouth combination chemotherapy in pregnancy is scarcely reported, with only 1 report of its use in the late second and third trimesters and no report of its use in the first trimester.
This is the first reported case in which the Dartmouth combination chemotherapy regimen was inadvertently used in a pregnant woman during the first and second trimesters for treatment of metastatic melanoma. The infant was found to have isolated microphthalmos and severe hypermetropia at 1 year of age.
Although a causal relationship cannot be established from a single case, this report does provide useful information to discourage the use of this chemotherapy regimen in the first trimester, which is the critical period for organogenesis.